tiprankstipranks
Trending News
More News >
Tivic Health Systems (TIVC)
NASDAQ:TIVC
US Market
Advertisement

Tivic Health Systems (TIVC) AI Stock Analysis

Compare
161 Followers

Top Page

TIVC

Tivic Health Systems

(NASDAQ:TIVC)

Rating:43Neutral
Price Target:
The overall stock score of 43 reflects Tivic Health Systems' current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock's technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

Tivic Health Systems (TIVC) vs. SPDR S&P 500 ETF (SPY)

Tivic Health Systems Business Overview & Revenue Model

Company DescriptionTivic Health Systems (TIVC) is a health technology company that focuses on developing and commercializing bioelectronic medicine solutions. It operates in the medical device sector, offering non-invasive products designed to treat chronic diseases and conditions. The company's flagship product, ClearUP Sinus Relief, is a handheld device that uses microcurrent waveforms to alleviate sinus pain and congestion caused by allergies, colds, and other sinus-related issues.
How the Company Makes MoneyTivic Health Systems generates revenue primarily through the sale of its medical devices, particularly ClearUP Sinus Relief. The company sells its products directly to consumers through online platforms and retail partnerships. Additionally, Tivic may collaborate with healthcare providers and distributors to expand its market reach. The company's earnings are also influenced by its ongoing research and development efforts to introduce new products and innovations in the bioelectronic medicine field, potentially opening additional revenue streams in the future.

Tivic Health Systems Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: -8.57%|
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment. While Tivic Health has demonstrated significant progress and potential in its biopharmaceutical initiatives, including promising developments with Entolimod and improved gross margins, the company faces challenges with declining revenue, increased operating expenses, and underperformance in its ClearUP sales.
Q2-2025 Updates
Positive Updates
Expansion into Biopharmaceutical Sector
Tivic Health has expanded into the biopharmaceutical sector, notably with the exclusive licensing of Statera Biopharma's TLR5 agonist assets, including the late-stage Phase III drug candidate, Entolimod.
Entolimod's Potential in ARS and Oncology
Entolimod has been granted Fast Track designation for ARS and an orphan drug designation for pediatric ARS. It also holds potential to treat radiation and chemotherapy side effects, tapping into a market valued between $19 billion and $24 billion.
Gross Margin Improvement
Gross margins increased to 63% in the second quarter from 21% a year ago, and to 67% for the first half of 2025 from 42% in the same period in 2024, due to reductions in product support and fulfillment costs.
Strategic Pipeline Realignment
Tivic is exiting the Consumer Health Tech business to focus on its prescription-based therapeutic pipeline, which includes biologic and bioelectronic therapies.
Financial Stability and Fundraising
Tivic raised $0.9 million through equity and preferred stock sales, with no debt on its balance sheet, ensuring progress towards GMP manufacturing validation for Entolimod.
Negative Updates
Decline in Revenue
Revenue net of returns totaled $86,000 for the quarter compared to $140,000 in the prior year quarter, and $156,000 for the first half of 2025 compared to $474,000 for the first half of 2024, due to decreased unit sales of ClearUP.
Increased Operating Expenses and Net Loss
Operating expenses increased to $2 million in Q2 2025 from $1.3 million in Q2 2024. Net loss was $1.9 million for Q2 2025 compared to $1.3 million in Q2 2024.
ClearUP Sales Underperformance
Sales of ClearUP did not meet expectations, leading to a strategic decision to exit the Consumer Health Tech business.
Company Guidance
During Tivic Health Systems' second quarter 2025 earnings call, key guidance included the strategic refocus on the biopharmaceutical market with a transition away from the consumer device market, exemplified by their licensing of Statera Biopharma’s TLR5 agonist assets. The company emphasized the potential of Entolimod, a late-stage Phase III drug candidate, in treating acute radiation syndrome (ARS) with opportunities for significant government contracts. Financially, Tivic reported a decline in net revenue to $86,000 for Q2 2025 from $140,000 in Q2 2024, attributed to reduced ClearUP device sales as marketing efforts were scaled back. Despite this, gross margins improved to 63% from 21% in the prior year due to cost reductions. Operating expenses rose to $2 million from $1.3 million, driven by increased R&D investments. The net loss widened to $1.9 million from $1.3 million, and cash reserves stood at $1.2 million as of June 30, 2025. The company secured $0.9 million post-quarter through equity-related activities, with plans to utilize remaining funds for GMP manufacturing validation of Entolimod, marking a pivotal step towards commercialization.

Tivic Health Systems Financial Statement Overview

Summary
Tivic Health Systems faces significant financial challenges with declining revenues, consistent losses, and negative cash flows. While the balance sheet shows a low debt level, reliance on external financing and a deteriorating asset base are concerns. Profitability and operational efficiency need improvement.
Income Statement
30
Negative
The income statement shows a concerning trajectory with declining revenues from $1,840,000 in 2022 to $780,000 in 2024 and consistent negative net income. Gross profit margins have deteriorated significantly, leading to negative EBIT and EBITDA margins. Despite these challenges, there was a slight improvement in the gross profit margin from negative to positive, but overall profitability remains weak.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with stockholders' equity exceeding total debt, resulting in a Debt-to-Equity Ratio of zero. However, total assets have been decreasing from $5,856,000 in 2022 to $2,807,000 in 2024, indicating asset deterioration. The equity ratio remains strong but declining equity and asset base are concerns.
Cash Flow
40
Negative
Cash flow analysis reveals negative operating cash flows, indicating operational challenges. Free cash flow remains negative, reflecting ongoing cash burn. Positive financing cash flows in recent years suggest reliance on external funding. The Free Cash Flow to Net Income Ratio is unfavorable, highlighting inefficiencies in cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue516.00K780.00K1.18M1.84M1.17M860.00K
Gross Profit-115.00K2.00K287.00K299.00K-129.00K-225.00K
EBITDA-5.73M-5.31M-8.06M-9.92M-6.65M-3.21M
Net Income-5.68M-5.66M-8.24M-10.10M-8.49M-4.08M
Balance Sheet
Total Assets3.78M2.81M5.16M5.86M15.04M1.53M
Cash, Cash Equivalents and Short-Term Investments669.00K2.00M3.40M3.52M12.97M1.04M
Total Debt0.000.00369.00K530.00K708.00K1.47M
Total Liabilities741.00K272.00K1.58M2.23M1.76M2.71M
Stockholders Equity3.04M2.54M3.58M3.63M13.27M-1.18M
Cash Flow
Free Cash Flow-4.95M-5.72M-8.63M-8.93M-5.61M-3.03M
Operating Cash Flow-4.95M-5.72M-8.51M-8.92M-5.61M-3.03M
Investing Cash Flow-526.00K0.00-118.00K-11.00K0.000.00
Financing Cash Flow4.47M4.33M8.51M-528.00K17.54M1.76M

Tivic Health Systems Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.20
Price Trends
50DMA
3.77
Negative
100DMA
4.08
Negative
200DMA
4.50
Negative
Market Momentum
MACD
-0.17
Positive
RSI
41.28
Neutral
STOCH
5.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIVC, the sentiment is Negative. The current price of 3.2 is below the 20-day moving average (MA) of 3.45, below the 50-day MA of 3.77, and below the 200-day MA of 4.50, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 5.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIVC.

Tivic Health Systems Risk Analysis

Tivic Health Systems disclosed 48 risk factors in its most recent earnings report. Tivic Health Systems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tivic Health Systems Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
50
Neutral
AU$2.46B3.1310.94%2.67%36.93%13.84%
45
Neutral
$6.88M-344.28%-50.34%48.98%
44
Neutral
$3.88M-179.11%37.61%68.37%
43
Neutral
$3.30M-160.96%-58.49%84.67%
38
Underperform
$4.80M-1294.96%14.74%-2.42%
29
Underperform
$1.94M-96.69%98.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TIVC
Tivic Health Systems
3.20
-2.62
-45.02%
HSDT
Helius Medical Technologies
5.99
-541.51
-98.91%
VTAK
Catheter Precision
2.98
-32.74
-91.66%
IVF
INVO Fertility
1.05
-29.19
-96.53%
BJDX
Bluejay Diagnostics
1.34
-9.10
-87.16%

Tivic Health Systems Corporate Events

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Tivic Health Regains Nasdaq Compliance
Positive
Apr 10, 2025

On April 10, 2025, Tivic Health Systems announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a series of events where the company faced potential delisting due to its stock price falling below $1.00 for 33 consecutive days in 2024. After implementing a reverse stock split and meeting the necessary requirements, Nasdaq confirmed compliance, allowing Tivic Health to maintain its market position and providing stability for its stakeholders.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

Tivic Health Systems’ stock faces challenges primarily due to weak financial performance characterized by declining revenues and consistent losses. Despite strategic transformations and potential growth in pharmaceuticals, the current financial health and bearish technical indicators significantly impact the stock’s attractiveness. The company’s efforts to diversify and strategic acquisitions offer future potential but are currently overshadowed by the need for improved operational efficiency and profitability.

To see Spark’s full report on TIVC stock, click here.

Private Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
Tivic Health Systems Enters Equity Purchase Agreement
Positive
Mar 21, 2025

On March 18, 2025, Tivic Health Systems entered into an Equity Purchase Agreement with Mast Hill Fund, allowing Tivic to sell up to $25 million in common stock over 24 months. This agreement provides Tivic with financial flexibility to support its strategic initiatives, including expanding its biopharmaceutical program and advancing its non-invasive cervical vagus nerve stimulation devices. The company also reported a 30% reduction in net loss for 2024, reflecting improved financial management. Tivic’s recent strategic moves, including acquiring rights to Entolimod™ and appointing new leadership, aim to enhance its market position and drive growth in the biotech sector.

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Tivic Health Systems Announces Reverse Stock Split
Neutral
Mar 5, 2025

Tivic Health Systems, Inc. announced a 1-for-17 reverse stock split of its common stock, effective March 7, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. The reverse split is part of the company’s compliance plan to maintain its Nasdaq listing, following a notification from Nasdaq about non-compliance due to the stock’s low trading price. The reverse split will adjust the number of shares and conversion prices, but will not affect the overall ownership percentage of stockholders, aiming to increase the stock price above the $1.00 requirement.

Executive/Board ChangesBusiness Operations and Strategy
Tivic Health Systems Appoints New COO and President
Positive
Feb 24, 2025

On February 18, 2025, Tivic Health Systems announced the appointment of Michael Handley as Chief Operating Officer and President of its Tivic Biopharma division. Handley, a seasoned professional with extensive experience in drug and device commercialization, will lead Tivic’s efforts to advance its newly licensed product, Entolimod, through regulatory approval and commercialization. This strategic move aims to expand Tivic’s biopharmaceutical capabilities and enhance its therapeutics pipeline, potentially increasing shareholder value.

Product-Related AnnouncementsBusiness Operations and Strategy
Tivic Health Systems Secures Licensing Agreement with Statera
Positive
Feb 12, 2025

On February 11, 2025, Tivic Health Systems entered into an exclusive licensing agreement with Statera Biopharma to acquire rights to the TLR5 agonist program, including Entolimod for treating Acute Radiation Syndrome (ARS), and options for additional indications. This agreement positions Tivic as a diversified therapeutics company with a broadened clinical pipeline, potentially leading to FDA approval for ARS treatment within 24 months. Tivic’s acquisition aligns with its strategic transformation towards tackling immune and autonomic dysregulation. The deal involves milestone and royalty payments and allows Tivic to expand its product offerings, potentially benefiting shareholders by managing investments strategically.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 30, 2025